Tan Sin Yee, Mei Wong Joyce Ling, Sim Yan Jinn, Wong Su Sie, Mohamed Elhassan Safa Abdelgadir, Tan Sean Hong, Ling Lim Grace Pei, Rong Tay Nicole Wuen, Annan Naveenya Chetty, Bhattamisra Subrat Kumar, Candasamy Mayuren
School of Pharmacy, International Medical University, No 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
School of Postgraduate Studies, International Medical University, No 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000, Kuala Lumpur, Malaysia.
Diabetes Metab Syndr. 2019 Jan-Feb;13(1):364-372. doi: 10.1016/j.dsx.2018.10.008. Epub 2018 Oct 10.
Type 1 and type 2 diabetes mellitus is a serious and lifelong condition commonly characterised by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function. Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading cause of high mortality and morbidity rate. Furthermore, diabetes confers a huge economic burden due to its management costs as well as its complications are skyrocketing. The conventional medications in diabetes treatment focusing on insulin secretion and insulin sensitisation cause unwanted side effects to patients and lead to incompliance as well as treatment failure. Besides insulin and oral hypoglycaemic agents, other treatments such as gene therapy and induced β-cells regeneration have not been widely introduced to manage diabetes. Therefore, this review aims to deliver an overview of the current conventional medications in diabetes, discovery of newer pharmacological drugs and gene therapy as a potential intervention of diabetes in the future.
1型和2型糖尿病是一种严重的终身疾病,其常见特征是由于胰岛素分泌不足或胰岛素敏感性及功能下降导致血糖水平异常升高。多年来,糖尿病的患病率在全球范围内呈上升趋势,它被列为高死亡率和高发病率的主要原因之一。此外,由于糖尿病的管理成本以及其并发症不断飙升,它带来了巨大的经济负担。糖尿病治疗中的传统药物主要侧重于胰岛素分泌和胰岛素增敏,会给患者带来不良副作用,并导致治疗依从性差以及治疗失败。除了胰岛素和口服降糖药外,其他治疗方法,如基因治疗和诱导β细胞再生,尚未广泛应用于糖尿病的管理。因此,本综述旨在概述当前糖尿病的传统药物、新型药理学药物的发现以及基因治疗作为未来糖尿病潜在干预措施的情况。